Caribou Biosciences (NASDAQ:CRBU) Insider Barbara Mcclung Sells 6,938 Shares of Stock

Caribou Biosciences, Inc. (NASDAQ:CRBU) insider Barbara Mcclung sold 6,938 shares of the business’s stock in a transaction that occurred on Tuesday, February 24th. The stock was sold at an average price of $1.96, for a total value of $13,598.48. Following the completion of the sale, the insider owned 481,564 shares of the company’s stock, valued at $943,865.44. The trade was a 1.42% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Caribou Biosciences Price Performance

Shares of NASDAQ CRBU opened at $2.14 on Wednesday. The stock has a market capitalization of $200.03 million, a P/E ratio of -1.26 and a beta of 2.61. Caribou Biosciences, Inc. has a one year low of $0.66 and a one year high of $3.54. The firm’s 50 day simple moving average is $1.61 and its two-hundred day simple moving average is $1.90.

Hedge Funds Weigh In On Caribou Biosciences

A number of institutional investors have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. boosted its stake in Caribou Biosciences by 80.0% during the fourth quarter. Russell Investments Group Ltd. now owns 24,347 shares of the company’s stock worth $39,000 after acquiring an additional 10,824 shares in the last quarter. Green Alpha Advisors LLC grew its stake in shares of Caribou Biosciences by 3.1% in the 4th quarter. Green Alpha Advisors LLC now owns 375,139 shares of the company’s stock worth $596,000 after buying an additional 11,440 shares during the last quarter. CWM LLC increased its position in Caribou Biosciences by 53.5% during the 2nd quarter. CWM LLC now owns 33,839 shares of the company’s stock valued at $43,000 after buying an additional 11,798 shares in the last quarter. R Squared Ltd purchased a new position in Caribou Biosciences during the third quarter valued at $29,000. Finally, Bronte Capital Management Pty Ltd. bought a new stake in Caribou Biosciences in the fourth quarter worth $25,000. Institutional investors own 77.51% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. Truist Financial set a $7.00 target price on shares of Caribou Biosciences in a research note on Tuesday, November 4th. HC Wainwright increased their price objective on Caribou Biosciences from $3.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, November 5th. Citigroup boosted their target price on Caribou Biosciences from $5.00 to $8.00 and gave the company a “buy” rating in a research note on Monday, November 3rd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Caribou Biosciences in a report on Wednesday, January 21st. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $8.00.

About Caribou Biosciences

Caribou Biosciences, Inc is a clinical-stage biopharmaceutical company that leverages its proprietary CRISPR-Cas gene-editing platform to develop transformative cell therapies and in vivo treatments for a range of cancers and genetic diseases. The company’s core technology enables precise modification of cellular genomes, allowing the design of engineered T-cell and NK-cell therapies aimed at improving safety, efficacy and persistence in patients with hematologic and solid tumor malignancies. Alongside its oncology portfolio, Caribou is advancing in vivo editing programs targeting monogenic disorders, with initiatives in areas such as Duchenne muscular dystrophy and familial amyloidosis.

Established in 2011 and headquartered in Berkeley, California, Caribou Biosciences was co-founded by Nobel laureate Jennifer Doudna, one of the pioneers of CRISPR gene-editing technology.